{
    "organizations": [],
    "uuid": "06ab0383f3af5cca63eca8dbdf624d4953828491",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-therapeuticsmd-announces-fda-accep/brief-therapeuticsmd-announces-fda-acceptance-of-new-drug-application-for-tx-001hr-idUSASB0C9KG",
    "ord_in_thread": 0,
    "title": "BRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001Hr",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Therapeuticsmd Inc:\n* THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-001HR\n* THERAPEUTICSMD INC - PDUFA TARGET ACTION DATE FOR COMPLETION OF FDAâ€™S REVIEW IS OCTOBER 28, 2018 FOR TX-001HR Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-09T05:42:00.000+02:00",
    "crawled": "2018-03-09T14:11:44.022+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "therapeuticsmd",
        "inc",
        "therapeuticsmd",
        "announces",
        "fda",
        "acceptance",
        "new",
        "drug",
        "application",
        "nda",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "pdufa",
        "date",
        "therapeuticsmd",
        "inc",
        "pdufa",
        "target",
        "action",
        "date",
        "completion",
        "fda",
        "review",
        "october",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}